Re: K-V Pharmaceutical Co. Opiniones
http://biz.yahoo.com/e/131004/570558-k.html
KV Pharmaceutical Form 8-K
On September 27, 2013, the majority of the common stockholders of K-V Pharmaceutical Company
The equity bonus award will consist of (1) 3,751 shares of common stock (7,142 shares in the case of the Chairman) for each Eligible Director appointed or elected to the Board on or before December 31, 2013, and, in all other cases, a number of shares equal to $125,000 ($250,000 in the case of the Chairman) divided by the fair market value of one share as of the later of (x) December 31 of the immediately preceding calendar year and (y) the date on which the fair market value of such shares was last determined by the Company or, in the event of extraordinary conditions occurring after such date that materially affect such fair market value, such later date as may be determined by the Board in its sole discretion and (2) on each of the first three anniversaries of the initial grant date, subject to the Eligible Director's continued service on the Board as of such anniversary, a grant of shares of common stock in a number equal to $125,000 ($250,000 in the case of the Chairman) divided by the greater of (A) $32 and (B) the fair market value of one share as of the later of (x) December 31 of the immediately preceding calendar year and (y) the date on which the fair market value of such shares was last determined by the Company or, in the event of extraordinary conditions occurring after such date that materially affect such fair market value, such later date as may be determined by the Board in its sole discretion. Shares of common stock granted to an Eligible Director pursuant to an equity bonus award will be deferred and delivered to the Eligible Director as set forth in the form of Equity Bonus Agreement.
